The MHRA published its out-of-specification guidance in August 2013. Five years later, its inspectorate said the most common deficiency hadn't changed. Labs were still throwing out OOS results on assumptions, with no real evidence behind the decision. Cannabis flower is not exempt from that finding.
A cannabis OOS investigation is the documented process a Licensed Producer runs when a batch test result falls outside its approved specification. It moves in phases. You prove or rule out laboratory error with evidence, extend the investigation into cultivation and post-harvest if the lab is clean, then decide the batch's fate and check every related batch. EU importers and their Qualified Persons expect to read that file before they certify a Canadian batch.
Flower makes the job harder than it is for a tablet. It's a heterogeneous plant material, so two samples from one lot can legitimately read differently. That natural variability gives a weak investigation somewhere to hide.
What counts as an OOS result in cannabis testing
An out-of-specification result is any test result that falls outside the acceptance criteria in your specification, a pharmacopoeial monograph, or a customer's quality agreement. The FDA's OOS guidance uses that same scope and applies it to in-process tests as well as release tests. FDA first issued it in October 2006 and revised it in May 2022.
For a Canadian LP shipping flower to Europe, the specification usually stacks three layers. There's your own release specification, the import market's requirements, and the importer's quality agreement. A batch can pass one layer and fail another. Your OOS procedure has to trigger on all three.
OOT results need the same attention. An out-of-trend result sits inside the limit but breaks from batch history, such as a water activity reading well above your recent lots. MHRA guidance covers OOT and atypical results too, so a drifting method shouldn't wait for an outright failure before someone looks at it.
Four frameworks shape how the investigation is run and who signs it off:
| Framework | What it expects | Who owns the outcome |
|---|---|---|
| Health Canada, Cannabis Regulations s. 88 | QAP owns investigations and approves each lot before sale | Quality assurance person (QAP) |
| EU-GMP Guide, Chapter 6 | OOS and atypical trends investigated, confirmed OOS on marketed batches reported | Manufacturer, then the importer's QP |
| MHRA OOS guidance (2013, reviewed 2018) | Phases Ia, Ib, II and III, then batch disposition | Laboratory and QA |
| FDA OOS guidance (Rev. 1, 2022) | Phase I lab review, Phase II full-scale, no testing into compliance | Laboratory and quality unit |
If your SOP only fires on a hard failure against your own release spec, it's already behind what an EU inspector expects.
The 4-phase cannabis OOS investigation path
The MHRA and FDA documents use different labels, but the logic lines up. We use a four-phase structure, and each phase has to close with evidence before the next one starts.
Phase 1: Check for an obvious error
Before anything is discarded, the analyst and supervisor look for a clear, documentable error. Think calculation mistakes, the wrong reference standard, a failed system suitability test, or an instrument fault logged at the time. If the error is clear and recorded, the result is invalidated and the test is repeated. If it isn't clear, move on, and keep the original sample preparations.
Phase 2: Run a structured laboratory investigation
This phase works from a checklist and written hypotheses. Each hypothesis gets a planned test: re-inject the same extract to check for an instrument fault, or re-extract the original sample to check for a preparation error. QA approves the plan, including how many retests will run and how the results will be judged, before any retest starts. Where staffing allows, a second analyst performs the retest.
Phase 3: Extend into production
If the lab is cleared, the result stands and the investigation moves into the batch record. For flower, that means grow room conditions, pest control applications, and harvest date. It also means drying and curing logs, storage conditions, and the sampling event itself. The core question is whether the result is real for the whole lot or an artefact of where the sample came from. A weak sampling plan for batch testing makes that question impossible to answer.
Phase 4: Decide the batch and look sideways
Check every other lot from the same room, harvest window, or drying run, plus every sample run in the same instrument sequence. The QAP then records the decision: reject, rework where the specification and regulations allow it, or release only if the investigation proved the original result invalid. Confirmed failures go straight into your deviation and CAPA management process.
Phase 3 is where most cannabis investigations stall, because a lab can test a hypothesis in a day and a grow room can't.
Where cannabis OOS investigations break down
Most OOS files that get rejected by an auditor have sound chemistry behind them. The weak point is discipline, and the same four patterns come up repeatedly.
Invalidating without evidence
The MHRA inspectorate has described the old habit plainly: repeat the test twice more and hope for two passes. Two retests prove nothing statistically, and MHRA guidance points to published approaches built on 5, 7 or 9 retests instead. If you can't name the assignable cause and show the evidence, the original result is valid.
Testing into compliance
Retesting until a number passes, then reporting only the pass, is the first thing an auditor looks for. FDA guidance treats repeated testing to compliance as unacceptable. Every retest result, passing or failing, belongs in the file.
Averaging away real variability
Averaging a failing result with passing retests can hide a genuine problem. Both the FDA and MHRA documents limit averaging to cases the test method defines in advance. For potency, where bud-to-bud variation is real, that limit protects you.
Two labs, two numbers
Your Canadian ISO/IEC 17025 laboratory and the EU lab that retests on arrival will rarely match to the decimal. A gap outside the method's agreed variability is an OOS trigger on one side or the other. Both sites should run a single joint investigation, which is why EU retesting and COA discrepancies should be written into the quality agreement before the first shipment.
Our position is simple. A Canadian LP that can't show a closed, evidence-based OOS file for a batch shouldn't export that batch. The importer will find the gap during QP review, and a rejected shipment in Hamburg costs far more than a rejected lot in Montreal.
What EU importers expect to see in the OOS file
A complete OOS file shows the original result, every retest, the proven cause, and the batch decision. When a German or Swiss importer reviews a Canadian batch for EU QP batch release, the OOS file is read as evidence of how your quality system behaves under pressure. Expect the reviewer to look for:
- The original result and its raw data, including chromatograms and the instrument audit trail
- Written hypotheses and the QA-approved retest or resampling plan
- Every retest result, not only the passing ones
- The assignable cause, or a clear statement that none was found
- An impact assessment on related lots and on stock already shipped
- CAPA references and the QAP's signed batch decision
The file also has to keep working after the batch decision. OOS and OOT results belong in your annual cannabis product quality review, because one invalidated result is a mistake and three in a year on the same method is a pattern.
If a confirmed OOS touches a batch already on the market, Chapter 6 of the EU-GMP Guide expects the relevant competent authorities to be told. Your importer should hear it from you before they hear it from anyone else.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. Every batch carries ISO/IEC 17025 test data and full traceability, ships under export authorisation from the Cannabis Act, and comes with the investigation records that EU importers and their Qualified Persons ask to see.
Want to review how we document a batch before you commit to supply? Talk to our quality team. The file is ready.
Frequently Asked Questions
What does OOS mean in cannabis testing?
OOS stands for out of specification. It's any test result for a cannabis batch that falls outside the limits in the producer's specification, the import market's pharmacopoeial monograph, or the customer's quality agreement. A total THC result below the labelled range or a microbial count above its limit are common examples.
Can a Canadian LP retest a cannabis batch after an OOS result?
Yes, but only inside a documented investigation. Quality assurance should approve the retest plan, including the number of retests and how results will be judged, before testing starts. Every result must be reported, and both FDA and MHRA guidance reject retesting until a batch passes.
Who decides the outcome of an OOS investigation at a Canadian LP?
The quality assurance person. Section 88 of the Cannabis Regulations places investigations at processing licence holders under the QAP's responsibility and requires the QAP to approve every lot or batch before it's made available for sale. For EU export, the importer's Qualified Person makes a separate certification decision.
What is the difference between an OOS and an OOT result?
An OOS result is outside the specification limit. An OOT, or out-of-trend, result is still inside the limit but departs from batch history, such as an unusually high water activity reading. Both should be investigated, because an OOT result often signals a problem before it becomes a failure.
Does a confirmed OOS result have to be reported to regulators?
It can. Under Chapter 6 of the EU-GMP Guide, a confirmed OOS result affecting batches already released on the market should be reported to the relevant competent authorities. If product has shipped, recall and quality defect procedures may also apply in Canada and in the importing country.
